Skip to main content
Signal8
Launch Terminal

Annovis Bio, Inc. (ANVS)

Annovis Bio, Inc. is a clinical-stage biopharmaceutical company focused on pioneering treatments for neurodegenerative disorders. The firm's flagship drug, Buntanetap, an oral medication, has successfully advanced through Phase 2a clinical trials for Alzheimer's and Parkinson's diseases. This compound is also currently being evaluated in clinical studies for Alzheimer's disease in individuals with Down Syndrome, as well as for various other chronic neurodegenerative conditions. Beyond Buntanetap, Annovis Bio is developing ANVS405 to offer protection against traumatic brain injury and stroke. Additionally, ANVS301 is progressing through Phase I clinical trials, aiming to enhance cognitive capabilities in the later stages of Alzheimer's disease and broader dementia. The company was founded in 2008 and operates out of Berwyn, Pennsylvania.

Sector: Pharmaceutical Preparations

Industry: Biotechnology

Annovis Bio, Inc. logo

Annovis Bio, Inc.

NYSE:ANVSHealthcare
+10.78%$1.13
AH$1.12-0.57%vs close
Mkt Cap$48.23M
Float37.15M
O/S42.68M
Vol
$ Vol
RVOL
Inst Own25.3%
SI15.4%
Earnings
Dilution
Annovis Bio, Inc. logoNYSE:ANVS$1.13+10.78%
Phase Distribution
8 lead-sponsored trials·2 active·4 completed
Phase 11
Phase 1/22
Phase 2/33
Phase 32
Status Overview
Not yet recruiting1
Recruiting1
Active, not recruiting1
Completed4
Stopped1

Trials need funding. See this company's dilution risk and cash position.

Clinical Trials
Status
Phase
  • Phase 3
    Completed

    A Double-blind Study to Investigate Efficacy and Safety of Buntanetap Compared With Placebo in Participants With Early PD

    buntanetap/posiphen, Placebo

    Parkinson's Disease, Idiopathic

    Enrollment
    523
    Start
    Aug 2022
    Primary Completion
    Dec 2023
    Completion
    Dec 2023
    NCT05357989
  • Phase 3
    Active, not recruiting

    A Double-blind Dual Study Assessing Safety and Efficacy of Buntanetap in Participants With Early AD

    buntanetap/posiphen, Placebo

    Early Alzheimers Disease

    Enrollment
    760
    Start
    Feb 2025
    Primary Completion
    Dec 2027est.
    Completion
    Jun 2028est.
    NCT06709014
  • Phase 2/3
    Completed

    A Dose-ranging Study to Investigate Efficacy of Buntanetap in Mild to Moderate AD

    Buntanetap/Posiphen, Placebo

    Alzheimer Disease

    Enrollment
    351
    Start
    Apr 2023
    Primary Completion
    Feb 2024
    Completion
    Feb 2024
    NCT05686044
  • Phase 2/3
    Recruiting

    A Study of Buntanetap in Participants With PD

    buntanetap/posiphen

    Parkinson's Disease (PD), Deep Brain Stimulation

    Enrollment
    500
    Start
    Jan 2026
    Primary Completion
    Sep 2029est.
    Completion
    Nov 2029est.
    NCT07284784
  • Phase 2/3
    Not yet recruiting

    An Open-label Long-term Safety Study of Buntanetap in Participants With AD

    buntanetap/posiphen

    Alzheimer's Dementia (AD)

    Enrollment
    400
    Start
    Sep 2026est.
    Primary Completion
    Feb 2030est.
    Completion
    May 2030est.
    NCT07757204
  • Phase 1/2
    Completed

    Safety, Tolerability, PK and PD of Posiphen® in Subjects With Early Alzheimer's Disease

    Posiphen, Placebo

    Alzheimer's Disease

    Enrollment
    18
    Start
    Mar 2017
    Primary Completion
    Dec 2021
    Completion
    Dec 2021
    NCT02925650
  • Phase 1/2
    Completed

    Posiphen® Dose-Finding, Biomarker Study in Early Alzheimer's and Parkinson's Patients

    Posiphen, Placebo

    Alzheimer Disease, Parkinson Disease

    Enrollment
    75
    Start
    Aug 2020
    Primary Completion
    Aug 2021
    Completion
    Jan 2022
    NCT04524351
  • Phase 1
    Terminated

    Study of the Pharmacokinetics and Pharmacodynamics of POSIPHEN® in Subjects With Amnestic Mild Cognitive Impairment

    Posiphen® tartrate capsules

    Alzheimer's Disease, Amnestic Mild Cognitive Impairment

    Enrollment
    5
    Start
    Feb 2010
    Primary Completion
    Jul 2010
    Completion
    Jul 2010
    NCT01072812
Search ClinicalTrials.gov for “Annovis Bio”